Analysis Of The Weekly Performance Of Intellia Therapeutics Inc. (NTLA)


Intellia Therapeutics Inc. (NASDAQ:NTLA) finished Friday with a subtraction of -$0.39 to close at $34.89, a downside of -1.11 percent. An average of 867,000 shares of common stock have been traded in the last five days. There was a fall of -$1.18 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 1,425,505 shares traded, while the 50-day average volume stands at 1,147,872.

NTLA stock has decreased by -32.20% in the last month. The company shares reached their 1-month lowest point of $32.72 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $32.72 and a high of $126.95 in 52 weeks. It has reached a new high 1 time so far this year and lost -70.49% or -$83.35 in price. In spite of this, the price is down -72.52% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

NTLA stock investors should be aware that Intellia Therapeutics Inc. (NTLA) stock had its last reported insider trading activity 364 days ago on Jan 01. In this transaction, the insider spent $279,852. EVP, Chief Financial Officer, Goddard Glenn, disposed of 1,013 shares at a price of $112.24 on Jan 01. The insider now owns more than $113,699 worth of shares. Prior to that, EVP, Chief Scientific Officer Sepp-Lorenzino Laura went on to Sale 1,148 shares at $112.25 each on Jan 01. An amount of $128,863 was transacted.

Valuation Metrics

Intellia Therapeutics Inc. (NTLA) stock’s beta is 1.92. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 58.19, the price-to-book (PB) ratio at 3.22.

Financial Health

The quick ratio of Intellia Therapeutics Inc. for the three months ended September 29 was 6.60, and the current ratio was 6.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending September 29. Its gross profit as reported stood at $300.9 million compared to revenue of $33.05 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Intellia Therapeutics Inc.’s return on assets was -37.70%.

Earnings Surprise

The analyst consensus anticipated Intellia Therapeutics Inc.’s latest quarter earnings to come in at -$1.28 per share, but it turned out to be -$1.49, a -16.40% surprise. For the quarter, EBITDA amounted to -$103.58 million. Shareholders own equity worth $78.68 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Intellia Therapeutics Inc. (NTLA) price momentum. RSI 9-day as of the close on 30 December was 34.92%, suggesting the stock is Neutral, with historical volatility in this time frame at 43.90%.

As of today, NTLA’s price is $34.36 -3.27% or -$1.18 from its 5-day moving average. NTLA is currently trading -23.82% lower than its 20-day SMA and -42.24% lower than its 100-day SMA. However, the stock’s current price level is -33.80% below the SMA50 and -47.07% below the SMA200.

The stochastic %K and %D were 17.52% and 11.65%, respectively, and the average true range (ATR) was 2.15. With the 14-day stochastic at 20.84% and the average true range at 2.39, the RSI (14) stands at 33.68%. The stock has reached -0.58 on the 9-day MACD Oscillator while the 14-day reading was at -1.77.

Analyst Ratings

Morgan Stanley launched coverage on Intellia Therapeutics Inc. (NASDAQ: NTLA) in its analyst report released on October 11, 2022. The firm assigned the stock an Overweight rating. The consensus rating for Intellia Therapeutics Inc. (NTLA) among analysts is Buy. According to current brokerage recommendations, 1 brokerage firm advise that investors sell NTLA, while 3 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 21 others rate it as a “buy”.

What is NTLA’s price target for the next 12 months?

Analysts predict a range of price targets between $48.00 and $173.00, with a median target of $111.00. Taking a look at these predictions, the average price target given by analysts for Intellia Therapeutics Inc. (NTLA) stock is $109.04.


Please enter your comment!
Please enter your name here